Poseida Therapeutics Inc

Poseida Therapeutics — Technical Presentation (August 2021)

16 slides from Poseida Therapeutics's technical presentation, Aug 31, 2021

  1. Slide 1: P-PSMA-101 High-Tscm Autologous CAR-T Targeting PSMA in mCRPC

    P-PSMA-101 is a High-Tscm Autologous CAR-T Targeting PSMA Producing Exceptionally Deep and Durable Responses in Castration-Resistant Metastatic Prostate Cancer (mCRPC) August 31, 2021 Eric Ostertag, MD, PhD CEO, Poseida Therapeutics Exhibit 99.2

  2. Slide 2: Disclaimer

    Disclaimer This presentation and any accompanying oral commentary contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and include, without limitation, stat

  3. Slide 3: Overview

    Overview P-PSMA-101 is made using a unique CAR-T platform that results in a product comprised of a high percentage of T stem cell memory (TSCM) cells TSCM cells have bone marrow homing capability that may be particularly relevant to specific solid tumors, such as prostate adenocarcinoma At very low

  4. Slide 4: piggyBac: A Non-viral DNA Delivery System That Creates High-TSCM CAR-T Products

    piggyBac®: A Non-viral DNA Delivery System That Creates High-TSCM CAR-T Products TTAA ITR Insulator Promoter Poly(A) TTAA Insulator ITR Safety Switch CAR Molecule Selection Gene Non-viral gene insertion technology Enables efficient DNA integration & stable expression Multiple safety, timeline and co

  5. Slide 5: The Importance of Stem Cell Memory T Cells (TSCM)

    Normal PBMC controls (N=2) P-PSMA-101 clinical products (N=6) Stem Cell Memory TSCM Cell MORE DIFFERENTIATED LESS DIFFERENTIATED Products with High % of TSCM Cells STEMNESS MATTERS Strong correlation with best responses in the clinic More gradual tumor killing with less toxicity Better duration of r

  6. Slide 6: Phase 1 mCRPC Clinical Trial: P-PSMA-101-001

    Open Label, 3+3 Design, Dose Escalation + RP2D expansion, 40 patients Standard 3d lymphodepletion regimen: fludarabine 30 mg/m2 – CTX 300 mg/m2 Standard response criteria as per PCWG3: PSA, bone scans (BS)/CT, as well as exploratory biomarkers and novel tumor-targeted PET imaging (i.e., PSMA-PET, FD

  7. Slide 7: Demographics & Characteristics (Heavily Pretreated mCRPC Patients)

    Demographics & Characteristics (Heavily Pretreated mCRPC Patients) Parameter (n=9) Median (min, max) age, y 71 (57, 79) Median (min, max) time since diagnosis, y 6.4 (1, 23) ECOG (Baseline) PS, n (%), 0/1 6(67) / 3 (33) Median (min, max) prior regimens 6 (3, 15) LHRH agonist/antagonist 9 (100) bical

  8. Slide 8: Pharmacokinetics: Consistently High Expansion

    Pharmacokinetics: Consistently High Expansion Days after infusion -20 0 140 120 100 20 40 80 60 50 102 103 104 105 P-PSMA-101 / ug DNA Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 7 Patient 8 Most patients have significant CAR-T cell expansion in peripheral blood Many CAR-T products sho

  9. Slide 9: Efficacy: Exceptional Anti-Tumor Responses at the Lowest Dose Levels

    Marked decreases in PSA and PSMA-PET SUVs Efficacy: Exceptional Anti-Tumor Responses at the Lowest Dose Levels Pt 1 Pt 5 Pt 7 Pt 9 Pt 6 Pt 4 Pt 2 Pt 8 Pt 3 Received dexamethasone after CAR-T cells *central / local results

  10. Slide 10: Patient 3: Evidence of Complete Tumor Elimination

    PK, PSA, PSMA-PET, FDG-PET, Bone Scan (BS) & Pathology Correlate in Response Patient 3: Evidence of Complete Tumor Elimination 68Ga-PSMA-11 (PSMA-PET) FDG-PET BASELINE 4 WEEKS 12 WEEKS BASELINE 12 WEEKS BASELINE 12 WEEKS 50 102 103 104 105 0 10 20 30 40 Days after infusion PSA ng/mL -80 0 120 100 10

  11. Slide 11: Patient 3: Summary

    Patient 3: Summary 71 year-old male with mCRPC after 4 prior regimens, treated with 22 x 106 (0.25 X 106/kg) P-PSMA-101 CAR-T cells Evidence of potential complete tumor elimination >99% PSA decline with multiple values below 0.2 ng/mL over multiple months = possible PSA complete response Concordant

  12. Slide 12: Patient 8: Rapid Marked Response

    Early in the clinical course, with multiple response indicators correlating Patient 8: Rapid Marked Response 50 102 103 104 105 0 10 20 30 40 Days after infusion -80 0 120 100 10 30 80 60 20 40 110 90 70 50 P-PSMA-101 / ug DNA BASELINE 4 WEEKS BASELINE 4 WEEKS PSA PSMA-101 copies/ug DNA in periphera

  13. Slide 13: Adverse Events of Interest: Low Rate of Significant AEs

    Adverse Events of Interest: Low Rate of Significant AEs TEAE, n (%) Overall ≥ Grade 3 Dose Limiting Toxicity (DLT) 1 (11%) 1 (11%) Cytokine Release Syndrome (CRS)/transaminitisa 4 (44%) 1 (11%) CAR-T Related Encephalopathy Syndrome (CRES) 0 0 Neutropenia/Neutrophil count decreasedb 3 (33%) 3 (33%) T

  14. Slide 14: Summary: Exceptional Early Efficacy with Novel Anti-PSMA CAR-T Cell Product

    Summary P-PSMA-101 at very low doses induces deep and durable responses in heavily pretreated mCRPC patients Several patients with responses among the best ever described by a CAR-T product in a solid tumor indication Tscm cells have elevated bone homing markers - highly relevant in a bone predomina

  15. Slide 15: Acknowledgements

    With the greatest appreciation to the patients Acknowledgements P-PSMA-101-001 Investigators Memorial Sloan-Kettering Cancer Center Susan F. Slovin, M.D., Ph.D. City of Hope Tanya Dorff, M.D. Sarah Cannon Research Institute - HealthOne Denver Gerald Falchook, M.D. Dana-Farber Cancer Institute Xiao W

  16. Slide 16: Thank You

    Thank You The Next Wave of Cell & Gene Therapies with the Capacity to Cure

Poseida Therapeutics — Technical Presentation (August 2021) on 6ix